These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 31758256)
1. Correction to: Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. Sierra Morales F; Koralnik IJ; Gautam S; Samaan S; Sloane JA J Neurol; 2020 Jan; 267(1):132. PubMed ID: 31758256 [TBL] [Abstract][Full Text] [Related]
2. Correction to: Tyrosine-hydroxylase immunoreactivity in the mouse transparent brain and adrenal glands. Godefroy D; Rostène W; Anouar Y; Reaux-Le Goazigo A J Neural Transm (Vienna); 2019 May; 126(5):695. PubMed ID: 30448875 [TBL] [Abstract][Full Text] [Related]
3. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099 [TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490 [TBL] [Abstract][Full Text] [Related]
8. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070 [No Abstract] [Full Text] [Related]
9. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report. Harmel P; Schlunk F; Harms L Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444 [TBL] [Abstract][Full Text] [Related]
10. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Blair HA Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875 [TBL] [Abstract][Full Text] [Related]
11. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Ernst FR; Barr P; Elmor R; Wong SL Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152 [TBL] [Abstract][Full Text] [Related]
12. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179 [TBL] [Abstract][Full Text] [Related]
13. Diffuse dermatophytosis occurring on dimethyl fumarate therapy. Greenstein JI Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J; Chamoux C; Hammès F; Chicoye A PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055 [TBL] [Abstract][Full Text] [Related]
15. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188 [TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate for relapsing-remitting multiple sclerosis. Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591 [TBL] [Abstract][Full Text] [Related]
17. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031 [TBL] [Abstract][Full Text] [Related]
18. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699 [TBL] [Abstract][Full Text] [Related]